Study on combined of auranofin, salazosulfapyridine and methotrexate in rheumatoid arthritis

T. Fujii, A. Suwa, Tadashi Yoshida, T. Mimori, M. Akizuki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Patients with rheumatoid arthritis who did not respond sufficiently to auranofin therapy were devided into three groups to be continued on auranofin monotherapy (1), to be on combination therapy of auranofin and salazosulfapyridine (2) and to be given methotrexate concomitantly with auranofin (3), and clinical responses were compared in a prospective manner. Patients on combination therapy either with salazosulfapyridine or with methotrexate demonstrated higher improvement than those on continued auranofin monotherapy. No unknown side effects associated with monotherapy of any of the three compounds were seen in any of the three groups. The study suggests usefullness of combination therapy either with methotorexate or with salazosulfapyridine for patients who failed to respond sufficiently to auranofin.

Original languageEnglish
Pages (from-to)571-582
Number of pages12
JournalRyumachi
Volume34
Issue number3
Publication statusPublished - 1994

Fingerprint

Auranofin
Sulfasalazine
Methotrexate
Rheumatoid Arthritis
Therapeutics

Keywords

  • auranofin
  • combination therapy
  • methotrexate
  • rheumatoid arthritis
  • salazosulfapyridine

ASJC Scopus subject areas

  • Rheumatology

Cite this

Study on combined of auranofin, salazosulfapyridine and methotrexate in rheumatoid arthritis. / Fujii, T.; Suwa, A.; Yoshida, Tadashi; Mimori, T.; Akizuki, M.

In: Ryumachi, Vol. 34, No. 3, 1994, p. 571-582.

Research output: Contribution to journalArticle

Fujii, T, Suwa, A, Yoshida, T, Mimori, T & Akizuki, M 1994, 'Study on combined of auranofin, salazosulfapyridine and methotrexate in rheumatoid arthritis', Ryumachi, vol. 34, no. 3, pp. 571-582.
Fujii, T. ; Suwa, A. ; Yoshida, Tadashi ; Mimori, T. ; Akizuki, M. / Study on combined of auranofin, salazosulfapyridine and methotrexate in rheumatoid arthritis. In: Ryumachi. 1994 ; Vol. 34, No. 3. pp. 571-582.
@article{f5d19000632842b0a83e8a3b18df5b6a,
title = "Study on combined of auranofin, salazosulfapyridine and methotrexate in rheumatoid arthritis",
abstract = "Patients with rheumatoid arthritis who did not respond sufficiently to auranofin therapy were devided into three groups to be continued on auranofin monotherapy (1), to be on combination therapy of auranofin and salazosulfapyridine (2) and to be given methotrexate concomitantly with auranofin (3), and clinical responses were compared in a prospective manner. Patients on combination therapy either with salazosulfapyridine or with methotrexate demonstrated higher improvement than those on continued auranofin monotherapy. No unknown side effects associated with monotherapy of any of the three compounds were seen in any of the three groups. The study suggests usefullness of combination therapy either with methotorexate or with salazosulfapyridine for patients who failed to respond sufficiently to auranofin.",
keywords = "auranofin, combination therapy, methotrexate, rheumatoid arthritis, salazosulfapyridine",
author = "T. Fujii and A. Suwa and Tadashi Yoshida and T. Mimori and M. Akizuki",
year = "1994",
language = "English",
volume = "34",
pages = "571--582",
journal = "Ryumachi",
issn = "0300-9157",
publisher = "Nihon Ryumachi Gakkai",
number = "3",

}

TY - JOUR

T1 - Study on combined of auranofin, salazosulfapyridine and methotrexate in rheumatoid arthritis

AU - Fujii, T.

AU - Suwa, A.

AU - Yoshida, Tadashi

AU - Mimori, T.

AU - Akizuki, M.

PY - 1994

Y1 - 1994

N2 - Patients with rheumatoid arthritis who did not respond sufficiently to auranofin therapy were devided into three groups to be continued on auranofin monotherapy (1), to be on combination therapy of auranofin and salazosulfapyridine (2) and to be given methotrexate concomitantly with auranofin (3), and clinical responses were compared in a prospective manner. Patients on combination therapy either with salazosulfapyridine or with methotrexate demonstrated higher improvement than those on continued auranofin monotherapy. No unknown side effects associated with monotherapy of any of the three compounds were seen in any of the three groups. The study suggests usefullness of combination therapy either with methotorexate or with salazosulfapyridine for patients who failed to respond sufficiently to auranofin.

AB - Patients with rheumatoid arthritis who did not respond sufficiently to auranofin therapy were devided into three groups to be continued on auranofin monotherapy (1), to be on combination therapy of auranofin and salazosulfapyridine (2) and to be given methotrexate concomitantly with auranofin (3), and clinical responses were compared in a prospective manner. Patients on combination therapy either with salazosulfapyridine or with methotrexate demonstrated higher improvement than those on continued auranofin monotherapy. No unknown side effects associated with monotherapy of any of the three compounds were seen in any of the three groups. The study suggests usefullness of combination therapy either with methotorexate or with salazosulfapyridine for patients who failed to respond sufficiently to auranofin.

KW - auranofin

KW - combination therapy

KW - methotrexate

KW - rheumatoid arthritis

KW - salazosulfapyridine

UR - http://www.scopus.com/inward/record.url?scp=0028069102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028069102&partnerID=8YFLogxK

M3 - Article

C2 - 7914383

AN - SCOPUS:0028069102

VL - 34

SP - 571

EP - 582

JO - Ryumachi

JF - Ryumachi

SN - 0300-9157

IS - 3

ER -